Vertex Pharmaceuticals (VRTX)

Nasdaq Health Care Biotechnology S&P 500Nasdaq-100

$547.09

+4.59 (+0.85%)

Close of Nov 06, 2026 · end-of-day data

Source: Vertex Pharmaceuticals's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 04, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.70B	$2.49B	$3.05B	$4.16B	$6.21B	$7.57B	$8.93B	$9.87B	$11.02B	$12.00B
Cost of revenue	$210.46M	$275.12M	$409.54M	$547.80M	$736.30M	$904.20M	$1.08B	$1.26B	$1.53B	$1.65B
Gross profit	$1.49B	$2.21B	$2.64B	$3.62B	$5.47B	$6.67B	$7.85B	$8.61B	$9.49B	$10.35B
Research & development	$1.05B	$1.32B	$1.42B	$1.75B	$1.83B	$3.05B	$2.54B	$3.16B	$3.63B	$3.91B
Selling, general & admin	$432.83M	$496.08M	$557.62M	$658.50M	$770.50M	$840.10M	$944.70M	$1.14B	$1.46B	$1.75B
Operating income	$9.94M	$123.24M	$635.15M	$1.20B	$2.86B	$2.78B	$4.31B	$3.83B	-$232.90M	$4.17B
Interest expense	—	$69.30M	$72.47M	$58.50M	$58.15M	—	$54.80M	$44.10M	$30.60M	$13.30M
Pre-tax income	-$67.37M	-$15.69M	$600.24M	$1.39B	$3.12B	$2.73B	$4.23B	$4.38B	$248.50M	$4.64B
Income tax	$16.66M	-$107.32M	-$1.49B	$218.10M	$405.20M	$388.30M	$910.40M	$760.20M	$784.10M	$690.00M
Net income	-$112.05M	$263.48M	$2.10B	$1.18B	$2.71B	$2.34B	$3.32B	$3.62B	-$535.60M	$3.95B
EBITDA	$71.33M	$184.64M	$707.57M	$1.30B	$2.97B	$2.91B	$4.46B	$4.01B	-$25.70M	$4.38B
EPS (basic)	$-0.46	$1.06	$8.24	$4.58	$10.44	$9.09	$12.97	$14.05	$-2.08	$15.46
EPS (diluted)	$-0.46	$1.04	$8.09	$4.51	$10.29	$9.01	$12.82	$13.89	$-2.08	$15.32
Diluted shares	244.69M	253.22M	259.19M	260.70M	263.40M	259.90M	259.10M	260.50M	257.90M	258.00M
Gross margin	87.6%	88.9%	86.6%	86.8%	88.1%	88.1%	87.9%	87.2%	86.1%	86.2%
Operating margin	0.6%	5.0%	20.8%	28.8%	46.0%	36.7%	48.2%	38.8%	-2.1%	34.8%
Net margin	-6.6%	10.6%	68.8%	28.3%	43.7%	30.9%	37.2%	36.7%	-4.9%	32.9%

Balance sheet

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$1.18B	$1.67B	$2.65B	$3.11B	$5.99B	$6.79B	$10.50B	$10.37B	$4.57B	$5.08B
Short-term investments	—	$423.25M	$518.11M	$698.97M	$670.70M	$729.90M	$274.50M	$849.20M	$1.55B	$1.52B
Receivables	$200.36M	$281.34M	$409.69M	$633.52M	$885.40M	$1.14B	$1.44B	$1.56B	$1.61B	$2.05B
Inventory	$77.60M	$111.83M	$124.36M	$167.50M	$280.80M	$353.10M	$460.60M	$738.80M	$1.21B	$1.69B
Total current assets	$1.83B	$2.65B	$3.84B	$4.82B	$8.13B	$9.56B	$13.23B	$14.14B	$9.60B	$11.20B
Goodwill	$50.38M	$50.38M	$50.38M	$1.00B	$1.00B	$1.00B	$1.09B	$1.09B	$1.09B	$1.09B
Total assets	$2.90B	$3.55B	$6.25B	$8.32B	$11.75B	$13.43B	$18.15B	$22.73B	$22.53B	$25.64B
Total current liabilities	$792.54M	$807.26M	$1.12B	$1.33B	$1.88B	$2.14B	$2.74B	$3.55B	$3.56B	$3.86B
Short-term debt	—	—	—	—	—	—	—	—	—	$0
Long-term debt	$0	—	—	—	—	—	—	—	—	$0
Total debt	$0	—	—	—	—	—	—	—	—	$0
Total liabilities	$1.56B	$1.50B	$1.81B	$2.23B	$3.06B	$3.33B	$4.24B	$5.15B	$6.12B	$6.98B
Shareholders' equity	$1.16B	$2.03B	$4.44B	$6.09B	$8.69B	$10.10B	$13.91B	$17.58B	$16.41B	$18.67B

Cash flow

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	$236.10M	$844.94M	$1.27B	$1.57B	$3.25B	$2.64B	$4.13B	$3.54B	-$492.60M	$3.63B
Capital expenditures	$56.56M	$99.42M	$95.45M	$75.40M	$259.80M	$235.00M	$204.70M	$200.40M	$297.70M	$437.60M
Free cash flow	$179.54M	$745.52M	$1.17B	$1.49B	$2.99B	$2.41B	$3.93B	$3.34B	-$790.30M	$3.19B
Investing cash flow	$51.24M	-$483.33M	-$202.16M	-$1.24B	$99.40M	-$340.90M	-$321.10M	-$3.14B	-$3.77B	-$945.40M
Financing cash flow	$133.27M	$68.40M	-$71.22M	$126.80M	-$505.30M	-$1.48B	-$67.70M	-$562.20M	-$1.49B	-$2.26B
Share buybacks	$0	$0	$350.04M	$186.00M	$539.10M	$1.43B	$0	$427.60M	$1.18B	$2.02B
Stock-based compensation	$240.62M	$293.24M	$325.05M	$360.50M	$429.50M	$441.40M	$491.30M	$581.20M	$698.50M	$685.90M
Depreciation & amortization	$61.40M	$61.40M	$72.42M	$106.90M	$109.50M	$125.60M	$148.30M	$181.30M	$207.20M	$209.80M

Income statement

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	$2.52B	$2.69B	$2.65B	$2.77B	$2.91B	$2.77B	$2.96B	$3.08B	$3.19B	$2.99B	$3.33B	$3.44B
Cost of revenue	$368.00M	$342.60M	$371.90M	$392.60M	$423.40M	$363.00M	$407.50M	$414.80M	$466.00M	$392.80M	$489.20M	$526.10M
Gross profit	$2.15B	$2.35B	$2.27B	$2.38B	$2.49B	$2.41B	$2.56B	$2.66B	$2.72B	$2.59B	$2.84B	$2.91B
Research & development	$824.60M	$789.10M	$966.60M	$875.90M	$998.70M	$979.70M	$978.40M	$977.70M	$973.70M	$961.60M	$993.80M	$1.32B
Selling, general & admin	$369.10M	$342.70M	$372.20M	$371.80M	$377.60M	$396.40M	$424.60M	$445.10M	$487.00M	$493.70M	$582.20M	$844.10M
Operating income	$988.50M	$1.14B	-$3.51B	$1.12B	$1.03B	$630.10M	$1.15B	$1.19B	$1.21B	$1.14B	$1.25B	$712.90M
Interest expense	$10.60M	$10.40M	$9.90M	$7.50M	$2.80M	$3.00M	$3.70M	$3.30M	$3.30M	—	—	$36.00M
Pre-tax income	$1.15B	$1.28B	-$3.39B	$1.22B	$1.14B	$730.40M	$1.28B	$1.30B	$1.33B	$1.25B	$1.39B	$783.40M
Income tax	$178.80M	$179.50M	$202.40M	$178.70M	$223.50M	$84.10M	$250.10M	$215.90M	$139.90M	$221.50M	$292.00M	$129.80M
Net income	$968.80M	$1.10B	-$3.59B	$1.05B	$913.00M	$646.30M	$1.03B	$1.08B	$1.19B	$1.03B	$1.10B	$653.60M
EBITDA	$1.05B	$1.19B	-$3.46B	$1.17B	$1.07B	$678.50M	$1.20B	$1.24B	$1.26B	$1.19B	$1.30B	$782.10M
EPS (basic)	$3.76	$4.26	$-13.92	$4.05	$3.53	$2.52	$4.02	$4.24	$4.69	$4.06	$4.34	$2.58
EPS (diluted)	$3.71	$4.21	$-13.92	$4.01	$3.53	$2.49	$3.99	$4.20	$4.64	$4.02	$4.31	$2.56
Diluted shares	100.00K	261.10M	258.10M	261.00M	-200.00K	259.50M	258.90M	257.60M	-600.00K	256.30M	255.20M	255.20M
Gross margin	85.4%	87.3%	85.9%	85.8%	85.5%	86.9%	86.3%	86.5%	85.4%	86.8%	85.3%	84.7%
Operating margin	39.3%	42.4%	-132.9%	40.3%	35.2%	22.7%	38.8%	38.6%	37.8%	38.1%	37.4%	20.7%
Net margin	38.5%	40.9%	-135.8%	37.7%	31.4%	23.3%	34.8%	35.2%	37.3%	34.5%	33.0%	19.0%

Balance sheet

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Cash & equivalents	$10.37B	$9.16B	$4.58B	$5.24B	$4.57B	$4.67B	$4.97B	$4.94B	$5.08B	$5.49B	$6.14B	$4.98B
Short-term investments	$849.20M	$1.01B	$1.22B	$1.29B	$1.55B	$1.53B	$1.41B	$1.35B	$1.52B	$1.75B	$1.71B	$1.32B
Receivables	$1.56B	$1.79B	$1.66B	$1.75B	$1.61B	$1.81B	$1.89B	$1.95B	$2.05B	$2.00B	$2.13B	$2.31B
Inventory	$738.80M	$813.10M	$914.60M	$1.08B	$1.21B	$1.36B	$1.50B	$1.63B	$1.69B	$1.77B	$1.77B	$2.25B
Total current assets	$14.14B	$13.29B	$8.94B	$9.80B	$9.60B	$10.01B	$10.43B	$10.57B	$11.20B	$11.73B	$12.54B	$11.69B
Goodwill	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$1.09B	$2.42B
Total assets	$22.73B	$23.92B	$20.13B	$22.24B	$22.53B	$22.88B	$24.04B	$24.86B	$25.64B	$26.48B	$27.42B	$32.74B
Total current liabilities	$3.55B	$3.80B	$3.55B	$3.97B	$3.56B	$3.78B	$4.14B	$4.48B	$3.86B	$3.88B	$3.94B	$5.00B
Short-term debt	—	—	—	—	—	—	—	—	$0	—	—	$999.60M
Long-term debt	—	—	—	—	—	—	—	—	$0	—	—	$3.50B
Total debt	—	—	—	—	—	—	—	—	$0	—	—	$4.50B
Total liabilities	$5.15B	$5.37B	$5.36B	$6.61B	$6.12B	$6.38B	$6.86B	$7.54B	$6.98B	$7.12B	$7.18B	$11.83B
Shareholders' equity	$17.58B	$18.55B	$14.77B	$15.63B	$16.41B	$16.50B	$17.18B	$17.32B	$18.67B	$19.36B	$20.25B	$20.91B

Cash flow

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Operating cash flow	$234.60M	$1.31B	-$3.75B	$1.37B	$584.60M	$818.90M	$1.07B	$1.24B	$498.00M	$1.43B	$1.13B	$643.10M
Capital expenditures	$58.10M	$68.40M	$69.00M	$67.70M	$92.60M	$40.70M	$145.70M	$101.80M	$149.40M	$133.40M	$112.20M	$97.30M
Free cash flow	$176.50M	$1.24B	-$3.82B	$1.30B	$492.00M	$778.20M	$927.40M	$1.14B	$348.60M	$1.29B	$1.01B	$545.80M
Investing cash flow	-$886.50M	-$2.14B	-$463.70M	-$348.00M	-$821.90M	-$55.80M	-$484.50M	-$117.00M	-$288.10M	-$431.90M	-$45.80M	-$6.10B
Financing cash flow	-$119.80M	-$357.50M	-$358.60M	-$387.50M	-$391.30M	-$680.40M	-$349.20M	-$1.15B	-$77.20M	-$538.80M	-$426.70M	$4.30B
Share buybacks	$149.50M	$131.20M	$320.30M	$307.70M	$417.90M	$426.10M	$391.80M	$1.07B	$128.40M	$336.90M	$469.50M	$126.70M
Stock-based compensation	$208.60M	$191.90M	$154.20M	$184.60M	$167.80M	$166.10M	$167.30M	$194.90M	$157.60M	$166.40M	$170.20M	$174.40M
Depreciation & amortization	$59.00M	$53.50M	$54.00M	$53.20M	$46.50M	$48.40M	$51.70M	$54.00M	$55.70M	$55.90M	$56.50M	$69.20M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.